An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain

Pain Medicine (United States)

Volumn 13, Issue 7, 2012, Pages 897-907

  Corli, Oscar ^a   Montanari, Mauro ^a   Deandrea, Silvia ^a,b   Greco, Maria Teresa ^a   Villani, Walter ^a   Apolone, Giovanni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Clinica del Lavoro L Devoto   (Italy)

Author keywords

Cancer Pain; Opioids Dose Escalation; Opioids Effectiveness; Opioids Switch

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; FENTANYL; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; STEROID;

ADJUVANT THERAPY; ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; ITALY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PROSPECTIVE STUDY; STEROID THERAPY;

EID: 84863883152     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01408.x     Document Type: Article

References (34)

1. World Health Organization. Cancer Pain Relief: With a Guide to Opioid Availability. Geneva: World Health Organization; 1996.
2. Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer 2005;13:145-52.
3. Droney J, Levy J, Quigley C. Prescribing opioids in renal failure. J Opioid Manag 2007;3:309-16.
4. Rhee C, Broadbent AM. Palliation and liver failure: Palliative medications dosage guidelines. J Palliat Med 2007;10:677-85.
5. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66.
6. Reyes-Gibby CC, Shete S, Rakvåg T, etal. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30.
7. Ross JR, Riley J, Taegetmeyer AB, etal. Genetic variation and response to morphine in cancer patients: Catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008;112:1390-403.
8. Apolone G, Corli O, Caraceni A, etal. Pattern and quality of care of cancer pain management. Results from the cancer pain outcome research study group. Br J Cancer 2009;100:1566-74.
9. Caraceni A, Mendoza TR, Mencaglia E, etal. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996;65:87-92.
10. Viscusi ER, Reynolds L, Chung F, etal. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain. A RTC. JAMA 2004;291:1333-41.
11. Groenvold M, Petersen MA, Aaronson NK, etal. The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006;42:55-64.
12. Sweeney C, Bruera ED. Opioids side effects and management. In: Bruera ED, Portenoy RK, eds. Cancer Pain, Assessment and Management. Cambridge, UK: Cambridge University Press; 2003:150-70.
13. Kaasa S, Apolone G, Klepstad P, etal. Expert conference on cancer pain assessment and classification, the need for international consensus: Working proposals on international standards. BMJ Supportive & Palliative Care 2011;1:281-7.
14. Mercadante S, Fulfaro F, Casuccio A, Barresi L. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage 1999;18:347-52.
15. Lachin JM. Sample size determinations for rxc comparative trials. Biometrics 1977;33:315-24.
16. Freedman KB, Back S, Bernstein J. Sample size and statistical power of randomized, controlled trials in orthopaedics. J Bone Joint Surg Br 2001;83-B:397-402.
17. Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007;17:556-64.
18. He L, Fong J, von Zastrow M, Whistler JL. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002;108:271-82.
19. Keith DE, Anton B, Murray SR, etal. Mu-opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998;53:377-84.
20. Bailey CP, Connor M. Opioids: Cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005;5:60-8.
21. Gintzler AR, Chakrabarti S. Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci 2006;79:717-22.
22. Ammon-Treiber S, Hollt V. Morphine-induced changes of gene expression in the brain. Addict Biol 2005;10:81-9.
23. McClung CA, Nestler EJ, Zachariou V. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. J Neurosci 2005;25:6005-15.
24. Hack SP, Vaughan CW, Christie MJ. Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology 2003;45:575-84.
25. Bruera E, Belzile M, Pituskin E, etal. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16:3222-9.
26. Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncol 2000;39:941-7.
27. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89:2027-30.
28. Mucci-LoRusso P, Berman BS, Silberstein PT, etal. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239-49.
29. Ahmedzai S, Brooks D. Transdermal fentanyl vs sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13:254-61.
30. Clark AJ, Ahmedzai SH, Allan LG, etal. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28.
31. Payne R, Mathias SD, Pasta DJ, etal. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl vs oral morphine. J Clin Oncol 1998;16:1588-93.
32. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69.
33. Bruera E, Palmer JL, Bosnjak S, etal. Methadone vs morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22:185-92.
34. Mercadante S, Porzio G, Ferrera P, etal. Sustained-release oral morphine vs transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008;12:1040-6.